About the Company
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BCLI News
BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…
BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Phase 3b Trial Design Announced; SPA Submitted to the FDA On March 4, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) presented a poster ...
New ALS Treatments Face Regulatory Uncertainty
Despite the approval of two novel therapies for this uniformly fatal neurodegenerative disease, experts say regulatory standards and expectations are still evolving.
Zacks Launched the Israel 150 Platform
Zacks Investment Research, a leading provider of investment-related data, research, and commentary, proudly announces the launch of Zacks Israel 150 - This new platform focuses on Israeli companies ...
Optimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic Partnerships
Mayank Mamtani, an analyst from B.Riley Financial, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated ...
FDA approves expanded use of Bristol Myers CAR T-cell therapy
The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb's (NYSE:BMY) Breyanzi as the first and only CAR T-cell therapy for adults with ... Finally Trending Up Karuna Therapeutics ...
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq ... KER-050 (elritercept), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia ...
Loading the latest forecasts...